You are on page 1of 5

Daftar Pustaka

1. National Cancer Institute. Adult Brain Tumors Treatment. July 2015.
2. National Cancer Institute. Childhood Cerebral Astrocytoma/MalignantGlioma
Treatment. July 2015.
3. National Cancer Institute. Adult Brain Tumors Treatment. July 2015.
4. National Cancer Institute. Childhood Cerebral Astrocytoma/MalignantGlioma
Treatment. July 2015.
5. NCCN Clinical Practice Guidelines of Oncology. Central Nervous System Cancer.
V.I. 2015
6. Castro, MG, Cowen, R, Williamson, IK, et al. Current and FutureStrategies for the
Treatment of Malignant Brain tumors. Elsevier scienceinc, 2003.
7. Rees, Jeremy. Neurological Oncology. Medicine 32:10. 2004
8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification ofTumours of
The Central Nervous System. 4th Edition. Lyon : IARS Press,2007
9. Bozzeti F. Nutritional support of the oncology patient. Critical Reviewsin
Oncology/Hematology 2013;87:172-200
10. Miller KR, Wischmeyer PE, Taylor B, McClave SA. An EvidenceBasedapproach to
perioperative nutrition support in the elective surgerypatients. J Parenter Enteral 2013;
37:39S
11. Scanlon C. Brain Tumors. In: Marian M, Roberts S, editors. ClinicalNutrition for
Oncology Patients. Boston: Jones and Bartlett Publishers,2010, p.321-50.J
12. Jaffe RA., Schmiesing CA., Golianu B. Intracranial Surgery, padaAnesthesiologist’s
Manual of Surgical Procedures, ed. 5. WoltersKluwer Health. Philadelphia. 2014
13. Department of Essential Medicines and Pharmaceutical Policies –37WHO. WHO
guidelines on the pharmacological treatment of persistingpain in children with
medical illnesses. WHO Press. Perancis. 2012.
14. ESMO Guidelines Working Group. Clinical practice guidelines,Management of
cancer pain: ESMO clinical practice guidelines. Annalsof Oncology 23
(supplement7):vii139-vii154,2012
15. Surawicz TS, McCarthy BJ, Kupelian V, Jukich PJ, Bruner JM,Davis FG.
Descriptive epidemiology of primary brain and CNStumors: results from the Central
Brain Tumor Registry of the UnitedStates, 1990–1994. Neuro Oncol 1999; 1:14–25.
16. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M,Black PM.
Epidemiology of intracranial meningioma. Neurosurgery2005 Dec;57(6):1088-95.
17. Bondy M, Ligon BL. Epidemiology and etiology of intracranialmeningiomas: a
review. J Neurooncol 1996;29(3):197-205.
18. Whittle PR, Smith C, Navoo P, Collie D. Meningiomas. Lancet
2004May;363(9420):1535-43.
19. Nakamura M, Roser F, Michel J, Jacobs C, Samii M. The naturalhistory of incidental
meningiomas. Neurosurgery 2003 Jul;53(1):62-71.
20. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, JouvetA, et al. The
2007 WHO classification of tumours of the centralnervous system. Acta Neuropathol
2007 Aug;114(2):97-109.
21. Gosztonyi G, Slowik F, Pasztor E. Intracranial meningiomasdeveloping at long
intervals following low-dose x-ray irradiation ofthe head. J Neurooncol 2004
Oct;70(1):59-65.
22. Umansky F, Shoshan Y, Rosenthal G, Fairfeld S, Spektor S.Radiation-induced
meningiomas. Neurosurg Focus 2008;24(5):E7. 46
23. National Institute for Health and Clinical Excellence. Improvingoutcomes for people
with brain and other CNS tumours: the manual.Developed by the National
Collaborating Centre for Cancer.Published: June
2006.http://www.nice.org.uk/nicemedia/pdf/CSG_brain_manual.pdfAccessed:
September 16, 2009
24. 10. Bohan E, Glass-Macenka D. It’s not your “run-of-the-mill”meningioma:
characteristics differentiating low-grade from highgrademeningeal tumors. J Neurosci
Nurs 2009 June;41(3)124-8.
25. Yano S, Kuratsu JI, Kumamoto Brain Tumor Research Group.Indications for surgery
in patients with asymptomatic meningiomasbased on an extensive experience. J
Neurosurg 2006 Oct;105:538-43
26. Miramanoff RO, Dosoretz DE, Linggood RM, Ojemann RG, MartuzaRL.
Meningioma: analysis of recurrence and progression followingneurosurgical
resection. J Neurosurg 1985;62:18-24.
27. Stafford SL, Perry A, Suman VJ, Meyer FB, Scheithauer BW, LohseCM, et al.
Primarily resected meningiomas: outcomes and prognosticfactors in 581 Mayo Clinic
patients, 1978 through 1988. Mayo ClinProc 1998;73:936-42.
28. Rogers L, Mehta M. Role of radiation therapy in treating intracranialmeningiomas.
Neurosurg Focus 2007 Oct; 23(4):E4
29. Pasquier D, Bijmolt S, Veninga T, Rezvoy N, Villa S, Krengli M, etal. Atypical and
malignant meningioma: outcome and prognosticfactors in 119 irradiated patients. A
multicenter, retrospective study 47of the Rare Cancer Network. Int J Radiat Oncol
Biol Phys 2008Aug;71(5):1388-93.
30. Goldsmith BJ, Wara WM, Wilson CB, Larson DA. Postoperativeirradiation for
subtotally resected meningiomas: a retrospectiveanalysis of 140 patients treated from
1967 to 1990. J Neurosurg1994;80:195-201.
31. Milosevic MF, Frost PJ, Laperriere NJ, Wong CS, Simpson WJ.Radiotherapy for
atypical or malignant intracranial meningioma. Int JRadiat Oncol Biol Phys 1996
Mar;34(4):817-22.
32. Dziuk T, Woo S, Butler EB, Thornby J, Grossman R, Dennis WS, etal. Malignant
meningioma: an indication for initial aggressivesurgery and adjuvant radiotherapy. J
Neurooncol 1998;37:177-88.
33. Hug EB, Devries A, Thornton AF, Munzenride JE, Pardo FS,Hedley-Whyte ET, et al.
Management of atypical and malignantmeningiomas: role of high-dose, 3D-conformal
radiation therapy. JNeurooncol 2000 Jun;48(2):151-60.
34. Mohda A, Gutin PH. Diagnosis and treatment of atypical andanaplastic meningiomas:
a review. Neurosurgery 2005Sept;57(3):538-50.
35. Hakim R, Alexander E, Loeffler JS, Shrieve DC, Wen P, Fallon MP,et al. Results of
linear accelerator based radiosurgery for intracranialmeningiomas. Neurosurgery
1998;42:446-54.
36. Harris AE, Lee JY, Omalu B, Flickinger JC, Kondziolka D, LunsfordLD. The effect
of radiosurgery during management of aggressivemeningiomas. Surg Neurol 2003
Oct;60(4):298-305. 48
37. Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas:an overview of
diagnosis and treatment. Neurosurg Focus 2007Oct;23(4):E1.
38. Koide SS. Mifepristone: auxiliary therapeutic use in cancer andrelated disorders. J
Reprod Med 1998 Jul;43(7):551-60.
39. Grunberg SM, Weiss MH, Spitz IM, Ahmadi J, Sadun A, RussellCA, et al. Treatment
of unresectable meningioma with theantiprogesterone agent mifepristone. J Neurosurg
2001;74:861-6.
40. de Keizer RJW, Smit JWA. Mifepristone treatment in patients withsurgically
incurable sphenoid-ridge meningioma: a long-term followup.Eye 2004 Mar;18:954-8.
41. Schrell UMH, Rittig MG, Anders M, Koch UH, Marschalek R,Kiesewetter F, et al.
Hydroxyurea for the treatment of unresectableand recurrent meningiomas: II.
Decrease in the size of meningiomasin patients treated with hydroxyurea. J Neurosurg
1997;86(5):840-4.
42. Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, AbreyLE. Stabilization
of disease progression by hydroxyurea in patientswith recurrent or unresectable
meningioma. J Neurosurg 2002;97:341-6.
43. Newton HB, Slivka MA, Stevens C. Hydroxyurea chemotherapy forunresectable or
residual meningioma. J Neurooncol 2000;49:165-70.Mc Elveen JT, Saunders JE.
Tumors of Cerebellopontine angle:Neurootologic Aspects of Diagnosis.. Wilkins RH,
Rechangary SS.In: Neurosurgery. Second edition. Mc Graw-Hill. New york. P 3625-
32
44. Vestibular Schwannoma. Greenberg MS. In: Handbook ofNeurosurgery, seventh
edition. Thieme. New york. 2010. P 620-4Sampath P, Long DM. Acoustic Neuroma.
Winn HR. In: YoumansNeurological Surgery. Saunders. Philadelphia. p 1147-
6Canadian Cancer Society/National Cancer Institute of Canada.Canadian Cancer
Statistics 2009, Toronto, Canada, 2009.
45. Surawicz TS, MCCarthy BJ, Kupelian V, Jukich PJ, Bruner JM,Davis FG.
Descriptive epidemiology of primary brain and CNStumors: results from the central
brain tumor registry of the UnitedStates, 1990-1994. Neuro-oncol 1999 Jan;1(1):14-
25
46. . Hoffman S, Propp JM, McCarthy BJ. Temporal trends in incidence ofprimary brain
tumors in the United States, 1985-1999.Neuro-oncol2006 Jan;8:27-37.
47. Ezzat S, Asa SL, Couldwell WT, Barr CE, Dodge WE, Vance ML, etThe prevalence
of pituitary adenomas: a systematic review.Cancer 2004 Aug;101(3):613-9.
48. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitaryadenomas. Endocr Rev
1998;19(6):798-827.
49. Heaney AP. Pituitary tumour pathogenesis. Br Med Bulletin 2006;75and 76:81-97.
50. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA,Beckers A. High
prevalence of pituitary adenomas: a cross-sectionalstudy in the province of Liège,
Belgium. J CLin Endocrinol Metab2006 Dec;91(12):4769-75.
51. Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitaryadenomas: a
community-based, cross-sectional study in Banbury(Oxfordshire, UK). Clin
Endocrinol 2009 Jul;[Epub ahead of print].